NKMAX CO., Ltd. announced that it has received KRW 36 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Meritz Securities Co., Ltd., Meritz Capital Co., Ltd., Investment Arm
April 14, 2022
Share
On April 15, 2022, NKMAX CO., Ltd. closed the transaction.
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
NKMAX CO., Ltd. announced that it has received KRW 36 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Meritz Securities Co., Ltd., Meritz Capital Co., Ltd., Investment Arm
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
NKMAX CO., LTD. 